Cousins Properties (CUZ) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended December 2023, Cousins Properties (CUZ) reported revenue of $196.59 million, up 1.5% over the same period last year. EPS came in at $0.65, compared to $0.16 in the year-ago quarter.

The reported revenue represents a surprise of -2.85% over the Zacks Consensus Estimate of $202.36 million. With the consensus EPS estimate being $0.65, the company has not delivered EPS surprise.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Cousins Properties performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Other: $0.06 million versus $0.26 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -55.8% change.
• Revenues- Rental property: $196.59 million versus the three-analyst average estimate of $201.20 million. The reported number represents a year-over-year change of +1.5%.
• Revenues- Fee income: $0.33 million versus the three-analyst average estimate of $0.36 million. The reported number represents a year-over-year change of -56.1%.
• Net Earnings per Share (Diluted): $0.12 versus the four-analyst average estimate of $0.12.

*Zacks Names "Single Best Pick to Double"

*From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

*It’s credited with a "watershed medical breakthrough" and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.

*It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research